Back

Effects of Sacubitril/Valsartan on all-cause hospitalizations in heart failure: participant-level pooled analysis of PARADIGM-HF and PARAGON-HF

30 August 2024 (08:00 - 17:30)
Organised by: Logo
Congress Presentation Part of: Drug therapy for heart failure: what is new? Treatment ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Doctor Henri Lu

Lausanne University Hospital, Lausanne (Switzerland)

8 More presentations in this session

Presentation thumbnail
Tafamidis treatment for transthyretin amyloid cardiomyopathy: results from an open-label, early-access, long-term study extension in an all-comers population
Professor M. Crespo-Leiro (A Coruna, ES)
Abstract Slides Video
Presentation thumbnail
Efficacy of sotagliflozin by diabetes duration: a secondary analysis of SCORED
Doctor R. Aggarwal (Boston, US)
Abstract Slides Video
Presentation thumbnail
Effects of dapagliflozin in heart failure according to duration of type 2 diabetes: a patient-level meta-analysis of DAPA-HF and DELIVER
Doctor J. Butt (Copenhagen, DK)
Abstract Slides Video
Presentation thumbnail
Long-term follow-up of the TRED-HF trial
Miss L. Cheng (London, GB)
Abstract Slides Video
Presentation thumbnail
Utilization and safety of digoxin in patients with chronic heart failure and atrial fibrillation with rapid ventricular rate
Doctor K. Berge (Nordbyhagen, NO)
Abstract Slides Video

Access the full session

Session thumbnail
Drug therapy for heart failure: what is new?

The Event

Event poster

ESC Congress 2024

30 August - 2 September 2024
You may be interested in
thumbnail
Congress Presentation
Influence of ejection fraction on outcomes with sacubitril/valsartan in patients with worsening heart failure with EF>40%: the PARAGLIDE-HF Trial
thumbnail
Congress Presentation
Effects of sacubitril/valsartan in patients with heart failure with reduced ejection fraction and an eGFR below 30 ml/min/1.73 m2
thumbnail
Congress Presentation
Treatment with sacubitril/valsartan and improvement of ventricular-arterial coupling in heart failure with reduced ejection fraction

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources